Evotec SE

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EVOTEC JOINS FORCES WITH THE CROHN'S & COLITIS FOUNDATION'S IBD THERAPEUTICS INCUBATOR TO ADVANCE DRUG DISCOVERY AND IDENTIFY NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE ("IBD") THE COLLABORATION LEVERAGES EVOTEC'S END-TO-END INTEGRATED R&D PLATFORM TO ADVANCE DRUG DISCOVERY FOR TWO INNOVATIVE DRUG TARGETS ADDRESSING FIBROSIS AND IMPAIRED INTESTINAL BARRIER FUNCTION HAMBURG, GERMANY and NEW YORK, NY / ACCESSWIRE / January 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that the Company has joined forces with the Crohn's & Colitis Foundation ("the Foundation"), the leading non-profit organisation focused on both research and patient support for inflammatory bowel disease ("IBD"), which includes Crohn's disease and ulcerative colitis. Under the collaboration, Evotec joins forces with the Foundation's IBD Therapeutics Incubator programme that facilitates collaboration between the Foundation, academic researchers, and industry partners to translate groundbreaking basic research that was performed by academic researchers and identified by the Foundation into medical innovations for IBD patients.

Evotec and Crohn's & Colitis Foundation Enter Agreement to Advance Drug Discovery for Novel IBD Therapies

Evotec (NASDAQ: EVO ) stock is falling on Thursday after the drug discovery and development partner announced the resignation of CEO Dr. Werner Lanthaler. According to a press release from the company, Lanthaler departure is immediate and won't see him finish his term as leader of the company.

Why Is Evotec (EVO) Stock Down 12% Today?

PARTNERSHIP COMBINES OWKIN'S A.I. TARGET DISCOVERY CAPABILITIES WITH EVOTEC'S INTEGRATED END-TO-END SHARED R&D PLATFORM A.I.

Evotec and Owkin Enter an A.I.-Powered Strategic Partnership to Accelerate Therapeutics Pipeline in Oncology and I&I

HAMBURG, GERMANY / ACCESSWIRE / January 3, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to step down as CEO and will not continue to serve until the end of his current term, for personal reasons. The Supervisory Board has accepted his resignation from his office.

Evotec Announces CEO Transition

EVOTEC JOINS THE BILL & MELINDA GATES FOUNDATION FUNDED GLOBAL HEALTH DISCOVERY COLLABORATORY ("GHDC") AS A NEW ADDITION TO THE FIFTEEN COLLABORATORY PLATFORMS GRANT FROM THE BILL & MELINDA GATES FOUNDATION PROVIDES GHDC MEMBER INSTITUTIONS WITH ACCESS TO EVOTEC'S IPSC-DERIVED HIGH-THROUGHPUT TERATOGENICITY PLATFORM HAMBURG, GERMANY / ACCESSWIRE / December 19, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has received a US$ 2.5 m grant from the Bill & Melinda Gates Foundation ("the foundation") for its teratogenicity platform, and joins the foundation's prestigious Global Health Discovery Collaboratory ("GHDC"), a network of researchers, centres of excellence, and technology platforms working together to accelerate the discovery and translation of global health interventions. Potential teratogenicity of drug candidates, i.e.

Evotec receives US$ 2.5 M Grant to Leverage Human iPSC-Derived Teratogenicity Platform for Global Health Programmes

GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF ANCA-ASSOCIATED VASCULITIS CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN WILL COLLECT BIOSAMPLES FROM ANCA-ASSOCIATED VASCULITIS PATIENTS EVOTEC WILL LEVERAGE ITS UNIQUE PANOMICS TECHNOLOGIES TO IMPROVE PATIENT STRATIFICATION AND CREATE NEW ENTRY POINTS FOR PRECISION MEDICINE DRUG DISCOVERY HAMBURG, GERMANY / ACCESSWIRE / December 14, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered a partnership with Charité Universitätsmedizin Berlin ("Charité"), one of the leading and largest university hospitals in Europe, to generate a molecular patient database for ANCA-associated vasculitis ("AAV"), a collection of relatively rare autoimmune diseases of unknown cause, characterised by inflammation of blood vessels. The strategic partnership between Evotec and Charité aims at achieving a better disease understanding of AAV by creating a unique longitudinal PanOmics database from the analysis of patient material.

Evotec Enters Partnership with Charité to Expand Molecular Patient Database in Autoimmune Diseases

EVT201 APPROVED BY THE CHINESE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ("NMPA") AS A NOVEL SHORT-TERM TREATMENT OF INSOMNIA EVOTEC'S LICENCE PARTNER ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD ("JINGXIN") WILL LEAD ALL COMMERCIALISATION EFFORTS FOR EVT201 IN CHINA AND SOUTH KOREA HAMBURG, GERMANY / ACCESSWIRE / December 6, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN:DE0005664809)(NASDAQ:EVO) announced today that Zhejiang Jingxin Pharmaceutical Co., Ltd ("Jingxin") has received the approval from the Chinese National Medical Products Administration ("NMPA") for the novel insomnia treatment EVT201, also known as Dimdazenil in China.

Evotec-partner Jingxin Receives Approval for EVT201 in China

PRECISION MEDICINE CAPABILITIES SHAPING (NEW) MARKETS WITH FIRST-IN-CLASS THERAPEUTICS PANOMICS, IPSC & A.I./M.L. PLATFORMS ARE THE STEP CHANGE FOR GROWTH AND ACCELERATED PIPELINE BUILDING CONFIRMATION OF ACTION PLAN 2025 GOALS AND PROGRESS UPDATE HAMBURG, GERMANY / ACCESSWIRE / November 15, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today presents at its Capital Markets Day how the Company is driving more efficient pipeline building towards assets, that are progressing with higher probabilities of success.

Evotec Presents Precision Medicine Platforms for Accelerated Pipeline Building at Capital Markets Day

Evotec SE's appeal is based on its valuation and upside potential in the drug discovery and development sector. The company's financial performance is average, with negative margins and subpar business model specifics for 2022. Despite some issues, EVO remains a leading player in the drug/pharma market with strong partnerships and revenue growth.

Evotec: Attractive Spec 'Buy', But Merck KGaA Is Still Better

Evotec SE (NASDAQ:EVO ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Laetitia Rouxel - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operating Officer Matthias Evers - Chief Business Officer Conference Call Participants Kirsty Ross-Stewart - Citi Charles Weston - RBC Capital Markets Pippa Pritchard - Morgan Stanley Michael Ryskin - Bank of America Steven Mah - TD Cowen Werner Lanthaler Welcome to our -- good morning. Good afternoon.

Evotec SE (EVO) Q3 2023 Earnings Call Transcript

CONTINUATION OF STRONG GROWTH IN DEMANDING MARKETS PARADIGM-SHIFTING OFFERINGS ARE STRONGEST GROWTH DRIVERS PIPELINE PROGRESS, E.G. WITH ADVANCED ASSET IN NEURODEGENERATION ALL ELEMENTS OF GUIDANCE CONFIRMED HAMBURG, GERMANY / ACCESSWIRE / November 8, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced the financial results and corporate updates for the first nine months 2023.

Evotec SE Reports Results for the First Nine Months 2023 and Provides Corporate Update

STRATEGIC PARTNERSHIP TO ACCELERATE DEWPOINT'S LEADING ONCOLOGY PIPELINE PROGRAMMES TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC'S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY PLATFORM AGREEMENT IS BASED ON A RISK-SHARING ARRANGEMENT FOLLOWED BY MILESTONE AND ROYALTY PAYMENTS TO EVOTEC BASED ON SUCCESS OF OVERALL PROGRAMMES HAMBURG, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Dewpoint Therapeutics today announced a strategic R&D collaboration to advance Dewpoint's leading oncology pipeline programmes of condensate modifying therapeutics ("c-mods") to Investigational New Drug Applications ("INDs") using Evotec's industry-leading fully integrated data-driven platform ("INDiGO"). The partnership brings together Dewpoint's advanced oncology pipeline programmes discovered using its groundbreaking condensate biology and A.I.

Evotec and Dewpoint Therapeutics Enter Strategic Partnership in Oncology

HAMBURG, Germany and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Dewpoint Therapeutics today announced a strategic R&D collaboration to advance Dewpoint's leading oncology pipeline programs of condensate modifying therapeutics (“c-mods”) to Investigational New Drug Applications (“INDs”) using Evotec's industry-leading fully integrated data-driven platform (“INDiGO”).

Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline

HAMBURG, GERMANY / ACCESSWIRE / November 1, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN:DE0005664809);(NASDAQ:EVO) will announce its financial results for the first nine months 2023 on Wednesday, 08 November 2023. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.

Evotec SE to Announce Results for the First Nine Months 2023 on 08 November 2023

A UNIQUE COMPANY CREATION VEHICLE INITIATED BY LIGHTSTONE VENTURES AND EVOTEC SE, AND ESTABLISHED WITH PARTNERS CLAVYSTBIO, LEAPS BY BAYER, POLARIS PARTNERS, AND THE POLARIS INNOVATION FUND FIRST-OF-ITS-KIND PARTNERSHIP IN SINGAPORE AND ASIA LEVERAGES BREAKTHROUGH SCIENCE FROM RESEARCHERS AT AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ("A*STAR") SINGAPORE, NATIONAL UNIVERSITY OF SINGAPORE ("NUS") AND DUKE-NUS MEDICAL SCHOOL, FOR GLOBAL HEALTH IMPACT NEW INCUBATOR WILL ACCELERATE TRANSLATION OF PROMISING ACADEMIC PROJECTS TO COMMERCIALISATION THROUGH CREATION OF NEW COMPANIES FOCUSED ON BREAKTHROUGH THERAPEUTICS AND SUPPORT THE GROWTH OF SINGAPORE'S BIOTECH ECOSYSTEM HAMBURG, GERMANY and SINGAPORE, SINGAPORE / ACCESSWIRE / October 5, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that the Company has entered into a new BRIDGE partnership with Lightstone Ventures, ClavystBio, Leaps by Bayer, Polaris Partners, and the Polaris Innovation Fund. "65LAB", Evotec's first academic BRIDGE in Asia, aims to advance drug discovery and the creation of new therapeutics companies in Singapore.

Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'

LABCENTRAL, BIOLABS, MBC BIOLABS PARTNER WITH EVOTEC TO SUPPORT BIOTECH INNOVATORS THROUGH CRITICAL INFLECTION POINTS AGREEMENT LEVERAGES EVOTEC'S INTEGRATED END-TO-END SHARED R&D PLATFORM TO ENABLE GREATER ACCESS TO INDUSTRY-GRADE CAPABILITIES AND DRUG HUNTING EXPERTISE FOR LIFE SCIENCES AND BIOTECH STARTUPS ACROSS THE GLOBAL LABCENTRAL / BIOLABS / MBC BIOLABS NETWORK ALL PARTIES PLAY SYNERGISTIC ROLES IN SUPPORTING AND FOSTERING THE SHARED R&D ECONOMY INNOVATION ECOSYSTEM HAMBURG, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / September 27, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO), LabCentral, a launchpad for high-potential life science and biotech start-ups, BioLabs, an international membership based network of shared lab and office facilities, and MBC BioLabs, premier providers of co-working laboratory space, today announced an agreement to boost early-stage innovations through access to Evotec's leading shared end-to-end R&D platform. The agreement will empower LabCentral / BioLabs / MBC BioLabs's network of promising early-stage life science and biotech companies by enhanced access to Evotec's industry-leading, innovative end-to-end platform and latest technologies for successful drug discovery and development to translate innovative life science research into new, improved ways to treat patients.

Evotec SE: Launch of Partnering Agreement to Strengthen Biotech Innovators in Shared R&D Economy

LAB eN² WILL INVOLVE INSTITUTIONS INCLUDING HARVARD UNIVERSITY, MASS GENERAL BRIGHAM, AND BETH ISRAEL DEACONESS MEDICAL CENTER FOCUS OF THE COLLABORATION IS TO ACCELERATE THE TRANSLATION OF ACADEMIC IDEAS TO THERAPEUTIC PRODUCT CANDIDATES IN THE CARDIOMETABOLIC SPACE HAMBURG, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / September 26, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) and Novo Nordisk today announced LAB eN² (pronounced Lab ee - en - squared), a translational drug discovery accelerator that aims to nurture early research from academic institutions into novel therapeutics. The focus is on addressing unmet need in cardiometabolic diseases as well as rare blood and rare endocrine disorders.

Evotec and Novo Nordisk Launch LAB eN(2) to Accelerate Translation in Cardiometabolic Diseases

Evotec SE (OTCPK:EVOTF) Q2 2023 Earnings Conference Call August 29, 2023 8:00 AM ET Company Participants Werner Lanthaler - CEO Laetitia Rouxel - CFO Cord Dohrmann - CSO Matthias Evers - Chief Business Officer Conference Call Participants Peter Verdult - Citigroup James Quigley - Morgan Stanley Wolf Chanoff - Bank of America Steven Mah - TD Cowen Joseph Hedden - Rx Securities Charles Weston - RBC Capital Markets Douglas Tsao - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by.

Evotec SE (EVOTF) Q2 2023 Earnings Call Transcript

NEW AND EXTENDED ALLIANCES UNDERLINE PIPELINE VALUE POTENTIAL NEW GUIDANCE FOR FULL-YEAR 2023 CONFIRMED HAMBURG, GERMANY / ACCESSWIRE / August 29, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced its financial results and corporate updates for the first half-year of 2023. HIGHLIGHTS Q2 CYBER-INCIDENT TEMPORARILY REDUNCING STRONG ORGANIC REVENUE GROWTH Group revenues increased by 14% to € 383.8 m (H1 2022: € 336.9 m) driven by strong demand for base business and successful partnering activities; like-for-like revenue growth (excluding fx-effects and M&A effects) 14% Total EVT Execute revenues (incl.

Evotec SE Reports Results for the First Half-year 2023 and Provides Corporate Updates

HAMBURG, GERMANY / ACCESSWIRE / August 22, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first half-year of 2023 on Tuesday, 29 August 2023. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.

Evotec SE Reports First Half-Year 2023 Results on 29 August 2023

HAMBURG, GERMANY / ACCESSWIRE / July 27, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that it is adjusting its guidance for the fiscal year 2023 due to the impact of the cyber-attack. For the current fiscal year, the company now expects Group revenues in the range of € 750 - 790 m (previously € 820 - 840 m); unpartnered R&D is expected in a range of € 60 - 70 m (previously € 70 - 80 m); and the adjusted EBITDA is expected to reach € 60 - 80 m (previously € 115 - 130 m).

Evotec Provides Update on Financial Impact of Cyber-Attack

Bristol-Myers

EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATION SELECTED PROGRAMMES FURTHER STRENGTHEN THE PROGRAMME PIPELINE OF NEURODEGENERATION ASSETS EVOTEC RECEIVES $ 40 M PAYMENT AND IS ELIGIBLE TO EARN PERFORMANCE MILESTONE PAYMENTS, AS WELL AS TIERED ROYALTIES UP TO LOW DOUBLE-DIGIT PERCENTAGES ON PRODUCT SALES HAMBURG, GERMANY / ACCESSWIRE / July 11, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that Bristol Myers Squibb Company (NYSE:BMY) has exercised its option to enter into an exclusive global licence agreement. The licence covers selected late-stage discovery programmes that were developed and progressed within the collaboration.

Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership

Evotec's Seattle-based subsidiary has won a $74 million contract with the U.S. Department of Defence to develop monoclonal antibody-based drugs targeting orthopoxviruses, the German biotech firm said on Wednesday.

Evotec wins orthopoxvirus antibody contract from U.S. government

JUST - EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS MABS TARGETING ORTHOPOXVIRUSES PROJECT INCLUDES EXISTING ANTIBODY DEVELOPMENT, ANTIBODY DISCOVERY, AND AI-DRIVEN DE NOVO ANTIBODY DESIGN OF THERAPEUTIC CANDIDATES EVOTEC WILL PROVIDE PRE-CLINICAL AND CLINICAL TRIAL SERVICES HAMBURG, GERMANY / ACCESSWIRE / July 5, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that the U.S. Department of Defense ("DOD") has awarded Evotec's Seattle-based subsidiary, Just - Evotec Biologics, Inc. a contract valued up to $ 74 m for the rapid development of monoclonal antibody ("mAb")-based drug product prototypes targeting orthopoxviruses. Under the contract, Just - Evotec Biologics will develop drug product prototype(s) from discovery through the execution of Phase I first-in human ("FIH") clinical trials.

Just - Evotec Biologics Awarded Second Contract from U.S. Department of Defense Under Accelerated Antibodies Program

PHASE I CLINICAL TRIAL INITIATED TO EVALUATE SEMA3A MAB AS POTENTIAL TREATMENT FOR ALPORT SYNDROME FIRST DOSING OF FIRST STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 2 M TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / June 29, 2023 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that it is to receive a € 2 m milestone payment from Bayer AG, which is triggered by the first patient dosed in the clinical Phase I study of a kidney disease programme stemming from the Evotec-Bayer multi-target research collaboration in kidney diseases. The drug candidate, a monoclonal antibody ("mAb") targeting the protein Semaphorin-3A ("Sema3A") is being developed as a potential first-to-market treatment for Alport syndrome, a rare genetic kidney disease.

News for Evotec SE Stock (EVO)